emapalumab

Showing 1 posts of 1 posts found.

sobi_offices

Sobi acquire Novimmune in deal worth more than £400 million

June 13, 2019
Business Services, Research and Development R&D, emapalumab, immuno-oncology, immunology, pharma

Swedish rare disease specialist Sobi has agreed to buy Swiss firm Novimmune ion a deal worth more than £400 million. …

Latest content